Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus amylovorus

What does the research say about Lactobacillus amylovorus?

3 health outcomes synthesised

Lactobacillus amylovorus has been researched for 3 health outcomes, with the strongest evidence supporting improved growth performance and intestinal barrier function. The growth performance evidence includes 4 animal studies showing moderate beneficial effects, while intestinal barrier function data from 3 animal studies also indicates moderate benefits. No consistent effective dose has been established across studies, and all research has been conducted in animal models, limiting direct applicability to humans.

Strongest evidence: The strongest evidence is for improved growth performance (4 studies, all beneficial, moderate effect size) and improved intestinal barrier function (3 studies, all beneficial, moderate effect size). Both outcomes have low evidence strength due to small study counts and exclusive use of animal models (weaning pigs, piglets, lambs, Asian seabass, and mice). No specific dose ranges have been identified for either outcome, as effective dose data were not consistently reported across studies.

Mixed or weaker evidence: Reduced inflammation has very low evidence strength (4 studies, all beneficial, moderate effect size). The evidence is limited by a small study base dominated by animal and in vitro research; the only human-relevant data comes from a meta-analysis of postbiotics, which found a small reduction in C-reactive protein (-0.99 mg/L), but direct attribution to Lactobacillus amylovorus is unclear.

Effective dose patterns: No cross-cutting dose insights are available, as no synthesis provided effective dose data for any outcome.

Population insights: All three outcomes were studied primarily in non-human populations — piglets, lambs, Asian seabass, mice, and in vitro human monocytes. No human clinical trials are represented in the evidence base.

Notable caveats: The research is overwhelmingly positive across all three outcomes, which raises concern for publication bias. Evidence bases are small (3–4 studies each), and conclusions should be considered preliminary. Importantly, no human studies have been conducted for growth performance or intestinal barrier function, and the only human-relevant inflammation data is indirect.

Frequently asked

  • What is Lactobacillus amylovorus good for according to research?
    Research suggests Lactobacillus amylovorus may support improved growth performance, intestinal barrier function, and reduced inflammationament, but all evidence comes from small, non-human studies. For growth performance, 4 animal studies all reported beneficial effects, while 3 animal studies showed benefit for intestinal barrier function.
  • What dose of Lactobacillus amylovorus is typically used in studies?
    No consistent effective dose has been identified in the research. The available studies did not report standardized dose ranges, making it unclear what amount might be needed for any of the studied outcomes.
  • Who benefits most from Lactobacillus amylovorus?
    The research has been conducted exclusively in animal populations, including weaning pigs, intrauterine growth restricted piglets and mice, Asian seabass, weaned lambs, and pregnant sows. Human-relevant evidence is absent for growth performance and intestinal barrier function, and only indirect for inflammation.
  • Are there caveats or limitations in the research on Lactobacillus amylovorus?
    Yes, significant caveats include small study sizes (3–4 studies per outcome), lack of human clinical trials, and consistently positive results that suggest possible publication bias. All conclusions should be considered preliminary, and applicability to humans is uncertain.
  • Does Lactobacillus amylovorus help with growth performance?
    Four animal studies, primarily in piglets and lambs, all reported beneficial effects on growth performance, with 3 reaching statistical significance. However, this evidence is low quality, and no human studies have been conducted to confirm similar effects in people.
  • Does Lactobacillus amylovorus reduce inflammation?
    Four studies reported beneficial effects on reduced inflammation, but the evidence is very low quality. Most studies were in animals or in vitro, and the only human-relevant finding — a small reduction in CRP from a meta-analysis of postbiotics — could not be directly attributed to Lactobacillus amylovorus.

Most-studied combinations with Lactobacillus amylovorus

most supplement research is combination research
Also studied with:Lactobacillus acidophilus (2)
Back to top